{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T19:31:45Z","timestamp":1783366305708,"version":"3.54.6"},"reference-count":63,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bulcan.2024.11.013","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T08:27:57Z","timestamp":1741681677000},"page":"1193-1207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Le carcinome de Merkel\u00a0: mise au point"],"prefix":"10.1016","volume":"112","author":[{"given":"Louise","family":"Toumelin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Kervarrec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahtab","family":"Samimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2024.11.013_bib0320","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2018.02.003","article-title":"The association between geographic location and incidence of Merkel cell carcinoma in comparison to melanoma: an international assessment","volume":"94","author":"Stang","year":"2018","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2024.11.013_bib0325","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/jdv.14798","article-title":"Merkel cell carcinoma in France: a registries-based, comprehensive epidemiological survey","volume":"32","author":"Fondain","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"24","key":"10.1016\/j.bulcan.2024.11.013_bib0330","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.3390\/cancers14246176","article-title":"Epidemiology of Merkel cell polyomavirus infection and Merkel cell carcinoma","volume":"14","author":"Silling","year":"2022","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.bulcan.2024.11.013_bib0335","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1245\/s10434-016-5266-4","article-title":"Analysis of prognostic factors from 9387\u00a0Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system","volume":"23","author":"Harms","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.11.013_bib0340","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2007.11.020","article-title":"Clinical characteristics of Merkel cell carcinoma at diagnosis in 195\u00a0patients: the AEIOU features","volume":"58","author":"Heath","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.bulcan.2024.11.013_bib0345","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000337411","article-title":"Dermoscopy of Merkel cell carcinoma","volume":"224","author":"Dalle","year":"2012","journal-title":"Dermatology"},{"key":"10.1016\/j.bulcan.2024.11.013_bib0350","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3389\/fonc.2019.00451","article-title":"Histogenesis of Merkel cell carcinoma: a comprehensive review","volume":"9","author":"Kervarrec","year":"2019","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2024.11.013_bib0355","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5858\/2001-125-0228-IFTTFA","article-title":"Immunostaining for thyroid transcription factor 1\u00a0and cytokeratin 20\u00a0aids the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinomas","volume":"125","author":"Cheuk","year":"2001","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"10.1016\/j.bulcan.2024.11.013_bib0360","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41379-018-0155-y","article-title":"Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas","volume":"32","author":"Kervarrec","year":"2019","journal-title":"Mod Pathol"},{"issue":"5866","key":"10.1016\/j.bulcan.2024.11.013_bib0365","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1126\/science.1152586","article-title":"Clonal integration of a polyomavirus in human Merkel cell carcinoma","volume":"319","author":"Feng","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.bulcan.2024.11.013_bib0370","doi-asserted-by":"crossref","first-page":"200232","DOI":"10.1016\/j.tvr.2021.200232","article-title":"Merkel cell polyomavirus and associated Merkel cell carcinoma","volume":"13","author":"Yang","year":"2022","journal-title":"Tumour Virus Res"},{"issue":"11","key":"10.1016\/j.bulcan.2024.11.013_bib0375","doi-asserted-by":"crossref","first-page":"e0142329","DOI":"10.1371\/journal.pone.0142329","article-title":"Merkel cell polyomavirus small T antigen induces cancer and embryonic Merkel cell proliferation in a transgenic mouse model","volume":"10","author":"Shuda","year":"2015","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.bulcan.2024.11.013_bib0380","doi-asserted-by":"crossref","first-page":"32956","DOI":"10.18632\/oncotarget.8793","article-title":"RB1\u00a0is the crucial target of the Merkel cell polyomavirus large T antigen in Merkel cell carcinoma cells","volume":"7","author":"Hesbacher","year":"2016","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.bulcan.2024.11.013_bib0385","doi-asserted-by":"crossref","first-page":"e152069","DOI":"10.1172\/JCI152069","article-title":"Direct cellular reprogramming enables development of viral T antigen\u00a0\u2013\u00a0driven Merkel cell carcinoma in mice","volume":"132","author":"Verhaegen","year":"2022","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1016\/j.bulcan.2024.11.013_bib0390","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1158\/1078-0432.CCR-18-4159","article-title":"The Genomic landscape of Merkel cell carcinoma and clinicogenomic biomarkers of response to immune checkpoint inhibitor therapy","volume":"25","author":"Knepper","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.bulcan.2024.11.013_bib0395","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41379-021-00928-1","article-title":"Genomic evidence suggests that cutaneous neuroendocrine carcinomas can arise from squamous dysplastic precursors","volume":"35","author":"Harms","year":"2022","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.11.013_bib0400","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jid.2021.07.175","article-title":"Merkel cell polyomavirus\u00a0\u2013\u00a0negative Merkel cell carcinoma originating from in situ squamous cell carcinoma: a keratinocytic tumor with neuroendocrine differentiation","volume":"142","author":"Kervarrec","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.bulcan.2024.11.013_bib0405","doi-asserted-by":"crossref","first-page":"e1014","DOI":"10.1111\/jdv.19076","article-title":"Merkel cell carcinoma from renal transplant recipients are mostly MCPyV-negative and are frequently associated with squamous cell carcinomas or precursors","volume":"37","author":"Pacaud","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.11.013_bib0410","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.humpath.2014.12.001","article-title":"Merkel cell carcinoma: histopathologic and prognostic features according to the immunohistochemical expression of Merkel cell polyomavirus large T antigen correlated with viral load","volume":"46","author":"Leroux-Kozal","year":"2015","journal-title":"Hum Pathol"},{"issue":"8","key":"10.1016\/j.bulcan.2024.11.013_bib0415","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/cncr.30475","article-title":"Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: a prospective validation study","volume":"123","author":"Paulson","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2024.11.013_bib0420","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/bjd.14313","article-title":"Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1\u00a0protein in patients with Merkel cell carcinoma","volume":"174","author":"Samimi","year":"2016","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.bulcan.2024.11.013_bib0425","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jaad.2020.07.065","article-title":"Clinical benefit of baseline imaging in Merkel cell carcinoma: analysis of 584\u00a0patients","volume":"84","author":"Singh","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.bulcan.2024.11.013_bib0430","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/cam4.2781","article-title":"Patterns of distant metastases in 215\u00a0Merkel cell carcinoma patients: implications for prognosis and surveillance","volume":"9","author":"Lewis","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.bulcan.2024.11.013_bib0435","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ejca.2022.03.043","article-title":"Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline\u00a0\u2013\u00a0update 2022","volume":"171","author":"Gauci","year":"2022","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2024.11.013_bib0440","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/bjd.19021","article-title":"Sentinel lymph node positivity and overall survival in immunosuppressed patients with Merkel cell carcinoma: a national cohort study","volume":"183","author":"Song","year":"2020","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.bulcan.2024.11.013_bib0445","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.ejso.2017.05.013","article-title":"Prognostic factors in Merkel cell carcinoma patients undergoing sentinel node biopsy","volume":"43","author":"Mattavelli","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2024.11.013_bib0450","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/jso.27421","article-title":"Delayed time to radiation and overall survival in Merkel cell carcinoma","volume":"128","author":"Ma","year":"2023","journal-title":"J Surg Oncol"},{"issue":"1D","key":"10.1016\/j.bulcan.2024.11.013_bib0455","article-title":"NCCN Guidelines\u00ae insights: Merkel cell carcinoma, version 1.2024: featured updates to the NCCN guidelines","volume":"22","author":"Schmults","year":"2024","journal-title":"J Natl Compr Canc Netw [Internet]"},{"issue":"4","key":"10.1016\/j.bulcan.2024.11.013_bib0460","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/annonc\/mdr318","article-title":"Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study","volume":"23","author":"Jouary","year":"2012","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2024.11.013_bib0465","doi-asserted-by":"crossref","first-page":"102977","DOI":"10.1016\/j.esmoop.2024.102977","article-title":"Merkel-cell carcinoma: ESMO\u2013EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"9","author":"Lugowska","year":"2024","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.bulcan.2024.11.013_bib0470","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.amjsurg.2020.02.018","article-title":"Completion lymph node dissection for Merkel cell carcinoma","volume":"220","author":"Cramer","year":"2020","journal-title":"Am J Surg"},{"issue":"2","key":"10.1016\/j.bulcan.2024.11.013_bib0475","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1245\/s10434-018-7072-7","article-title":"Completion lymph node dissection or radiation therapy for sentinel node metastasis in Merkel cell carcinoma","volume":"26","author":"Lee","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"22","key":"10.1016\/j.bulcan.2024.11.013_bib0480","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1200\/JCO.20.00201","article-title":"Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358\u00a0trial","volume":"38","author":"Topalian","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2024.11.013_bib0485","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1245\/s10434-024-15478-4","article-title":"The role of neoadjuvant immunotherapy in the management of Merkel cell carcinoma with clinically detected regional lymph node metastasis","volume":"31","author":"Chang","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2024.11.013_bib0490","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw042","article-title":"Adjuvant radiation therapy and chemotherapy in Merkel cell carcinoma: survival analyses of 6908\u00a0cases from the national cancer database","volume":"108","author":"Bhatia","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"10404","key":"10.1016\/j.bulcan.2024.11.013_bib0495","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0140-6736(23)00769-9","article-title":"Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2\u00a0trial","volume":"402","author":"Becker","year":"2023","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.bulcan.2024.11.013_bib0500","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.2217\/fon-2017-0072","article-title":"Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma","volume":"13","author":"Nghiem","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.bulcan.2024.11.013_bib0505","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fonc.2018.00048","article-title":"Merkel cell carcinoma: an update and immunotherapy","volume":"8","author":"Uchi","year":"2018","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.013_bib0510","doi-asserted-by":"crossref","first-page":"e000674","DOI":"10.1136\/jitc-2020-000674","article-title":"Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2\u00a0JAVELIN Merkel 200\u00a0trial","volume":"8","author":"D\u2019Angelo","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2024.11.013_bib0515","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.esmoop.2021.100290","article-title":"Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after>5\u00a0years of follow-up","volume":"6","author":"D\u2019Angelo","year":"2021","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.bulcan.2024.11.013_bib0520","doi-asserted-by":"crossref","first-page":"e002646","DOI":"10.1136\/jitc-2021-002646","article-title":"First-line avelumab in a cohort of 116\u00a0patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study","volume":"9","author":"D\u2019Angelo","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2024.11.013_bib0525","doi-asserted-by":"crossref","first-page":"103461","DOI":"10.1016\/j.esmoop.2024.103461","article-title":"First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: 4-year follow-up from part B of the JAVELIN Merkel 200\u00a0study","volume":"9","author":"D\u2019Angelo","year":"2024","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.bulcan.2024.11.013_bib0530","doi-asserted-by":"crossref","first-page":"e002478","DOI":"10.1136\/jitc-2021-002478","article-title":"Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma","volume":"9","author":"Nghiem","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"13_Supplement","key":"10.1016\/j.bulcan.2024.11.013_bib0535","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-CT074","article-title":"Abstract CT074: non-comparative, open-label, multiple cohort, phase 1\/2\u00a0study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC)","volume":"77","author":"Topalian","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.bulcan.2024.11.013_bib0540","doi-asserted-by":"crossref","first-page":"S686","DOI":"10.1016\/j.annonc.2023.09.2280","article-title":"1146P updated results from POD1UM-201: a phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC)","volume":"34","author":"Grignani","year":"2023","journal-title":"Ann Oncol"},{"issue":"10357","key":"10.1016\/j.bulcan.2024.11.013_bib0555","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(22)01659-2","article-title":"Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2\u00a0trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2024.11.013_bib0560","doi-asserted-by":"crossref","unstructured":"Non-comparative, open-label, international, multicenter phase I\/II study of nivolumab (NIVO)\u00b1ipilimumab (IPI) in patients (pts) with recurrent\/metastatic Merkel cell carcinoma (MCC) (CheckMate 358).\u00a0|\u00a0Journal of Clinical Oncology [Internet]. [cit\u00e9 31\u00a0ao\u00fbt 2024]. Disponible sur\u00a0: https:\/\/ascopubs.org\/doi\/10.1200\/JCO. 2023.41.16_suppl.9506.","DOI":"10.1200\/JCO.2023.41.16_suppl.9506"},{"issue":"7","key":"10.1016\/j.bulcan.2024.11.013_bib0545","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/CJI.0000000000000432","article-title":"A retrospective study of ipilimumab plus nivolumab in anti-PD-L1\/PD-1\u00a0refractory Merkel cell carcinoma","volume":"45","author":"Shalhout","year":"2022","journal-title":"J Immunother"},{"issue":"11","key":"10.1016\/j.bulcan.2024.11.013_bib0550","doi-asserted-by":"crossref","first-page":"e005930","DOI":"10.1136\/jitc-2022-005930","article-title":"Ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma: a multicenter study of the prospective skin cancer registry ADOREG","volume":"10","author":"Glutsch","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.bulcan.2024.11.013_bib0565","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11864-016-0409-1","article-title":"Merkel cell carcinoma therapeutic update","volume":"17","author":"Cassler","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2024.11.013_bib0570","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjd.19150","article-title":"High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma","volume":"184","author":"Akaike","year":"2021","journal-title":"Br J Dermatol"},{"issue":"12, Supplement","key":"10.1016\/j.bulcan.2024.11.013_bib0575","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.annder.2018.09.142","article-title":"Traitement des carcinomes de Merkel inop\u00e9rables et\/ou m\u00e9tastatiques par analogue de la somatostatine. \u00c9tude nationale multicentrique mono-bras de phase II","volume":"145","author":"Leccia","year":"2018","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.bulcan.2024.11.013_bib0580","doi-asserted-by":"crossref","first-page":"9506","DOI":"10.1200\/JCO.2022.40.16_suppl.9506","article-title":"Navtemadlin (KRT-232) activity after failure of anti-PD-1\/L1 therapy in patients (pts) with TP53WT Merkel cell carcinoma (MCC)","volume":"40","author":"Wong","year":"2022","journal-title":"J Clin Oncol [Internet"},{"issue":"1","key":"10.1016\/j.bulcan.2024.11.013_bib0585","doi-asserted-by":"crossref","DOI":"10.5070\/D328157059","article-title":"Complete response of Merkel cell carcinoma with talimogene laherparepvec (TVEC) monotherapy","volume":"28","author":"Casale","year":"2022","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.bulcan.2024.11.013_bib0590","doi-asserted-by":"crossref","unstructured":"Phase 3\u00a0study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and\/or nodal metastases. |\u00a0Journal of Clinical Oncology [Internet]. [cit\u00e9 31\u00a0ao\u00fbt 2024]. Disponible sur: https:\/\/ascopubs.org\/doi\/10.1200\/JCO. 2024.42.17_suppl.LBA9501.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9501"},{"issue":"3","key":"10.1016\/j.bulcan.2024.11.013_bib0595","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/1078-0432.CCR-19-0972","article-title":"Intratumoral delivery of plasmid IL12\u00a0via electroporation leads to regression of injected and noninjected tumors in Merkel cell carcinoma","volume":"26","author":"Bhatia","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2024.11.013_bib0600","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2023.01.016","article-title":"Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation","volume":"183","author":"Weppler","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2024.11.013_bib0605","unstructured":"Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1\u00a0year and a PET\/CT-confirmed complete response\u00a0\u2013\u00a0PubMed [Internet]. [cit\u00e9 30\u00a0juill 2024]. Disponible sur\u00a0: https:\/\/pubmed.ncbi.nlm.nih.gov\/37788133\/."},{"issue":"11","key":"10.1016\/j.bulcan.2024.11.013_bib0610","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1007\/s00262-023-03539-8","article-title":"Extended duration of treatment using reduced-frequency dosing of anti-PD-1\u00a0therapy in patients with advanced melanoma and Merkel cell carcinoma","volume":"72","author":"Tachiki","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.bulcan.2024.11.013_bib0615","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40257-019-00427-9","article-title":"Immune checkpoint inhibitors and beyond: an overview of immune-based therapies in Merkel cell carcinoma","volume":"20","author":"Samimi","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.bulcan.2024.11.013_bib0620","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamadermatol.2021.6096","article-title":"Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis","volume":"158","author":"McEvoy","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"28","key":"10.1016\/j.bulcan.2024.11.013_bib0625","doi-asserted-by":"crossref","first-page":"26472","DOI":"10.18632\/oncotarget.4500","article-title":"Evaluating blood levels of neuron specific enolase, chromogranin A, and circulating tumor cells as Merkel cell carcinoma biomarkers","volume":"6","author":"Gaiser","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bulcan.2024.11.013_bib0315","unstructured":"Circulating tumor DNA assay detects Merkel cell carcinoma recurrence, disease progression, and minimal residual disease: surveillance and prognostic implications\u00a0|\u00a0Journal of Clinical Oncology [Internet]. [cit\u00e9 30\u00a0juill 2024]. Disponible sur\u00a0: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.23.02054?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20\u00a0%200pubmed."}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125000530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455125000530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:57:32Z","timestamp":1758301052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455125000530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0007455125000530"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.11.013","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Le carcinome de Merkel\u00a0: mise au point","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}